Suggested remit: To appraise the clinical and cost effectiveness of eptinezumab within its marketing authorisation for preventing migraine.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 3803

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
27 January 2022 - 24 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 November 2021 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual